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Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USASummary cells expressing Notch ligands and cells expressing Notch recep-Notch signaling is a crucial determinant of cell fate decision dur-
ing development and disease in several organs. Notch effects are
strictly dependent on the cellular context in which it is activated.
In the liver, Notch signaling is involved in biliary tree develop-
ment and tubulogenesis. Recent advances have shed light on
Notch as a critical player in liver regeneration and repair, as well
as in liver metabolism and inﬂammation and cancer. Notch sig-
naling is ﬁnely regulated at several levels. The complexity of
the pathway provides several possible targets for development
of therapeutic agents able to inhibit Notch. Recent reports have
shown that persistent activation of Notch signaling is associated
with liver malignancies, particularly hepatocellular with stem
cell features and cholangiocarcinoma. These novel ﬁndings sug-
gest that interfering with the aberrant activation of the Notch
pathway may have therapeutic relevance. However, further stud-
ies are needed to clarify the mechanisms regulating physiologic
and pathologic Notch activation in the adult liver, to better
understand the mechanistic role(s) of Notch in liver diseases
and to develop safe and speciﬁc therapeutic agents.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Notch signaling is a developmental pathway that regulates
several fundamental cellular processes including cell fate and dif-
ferentiation. Four transmembrane Notch receptors (Notch-1, -2,
-3, -4) and two types of ligands, Serrate/Jagged (Jag-1, -2) or
Delta-like (Dll-1, -3, -4) constitute the Notch system, along with
several other components that transduce and regulate the signal.
Activation of Notch signaling requires a direct contact betweenJournal of Hepatology 20
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Notch-2 intracellular domain; CCl4, carbon tetrachloride.tors; often both the ‘‘transmitting’’ and the ‘‘receiving’’ cells are
modiﬁed by their interaction. Initially cells express both Notch
receptor and ligands, but as the interaction continues, one cell
upregulates the ligands and down regulates the receptor, becom-
ing a ‘‘transmitting cell’’, whereas the opposite holds true for the
receiving cell [1]. Ligand-activated Notch receptors are cleaved by
the c-secretase complex, leading to the release of the Notch
intracellular domain (NICD). NICD translocates into the nucleus
where it, while binding the RBP-Jj transcription factor, displaces
the associated co-repressors and recruits associated co-activators
(i.e., MAML1) [2–5]. The signal culminates with the expression of
Notch target genes, such as the family of Hes and Hey related
transcription factors. Regarding the liver, Notch partly controls
also the expression of Sox9 and HNF1b, key players in hepatic
lineage commitment [6–8].
As expected from a signaling mechanism involved in organ
morphogenesis, Notch is ﬁnely tuned in a tissue- and time-
dependent fashion, and it is also controlled through post-transla-
tional modiﬁcations such as ubiquitination, glycosylation or
endocytosis. Continuous Notch activation requires constant
exposure to additional ligands, as NICD undergoes rapid prote-
asomal degradation [2–5]. Furthermore, the effects of Notch sig-
naling depend upon the cell types involved and the presence of
signals from other pathways, including Wnt and Hedgehog.
Studies based on rodent models of Notch loss or gain of func-
tion have demonstrated that Notch is involved in several stages of
intrahepatic bile duct (IHBD) morphogenesis [9]. Jag-1-positive
mesenchymal cells at the parenchymal/portal interface of the nas-
cent portal space induce the expression of cholangiocytes-speciﬁc
markers in adjacent hepatoblasts, committing them to the biliary
lineage. Furthermore, by regulating Sox9 and HNF1b, Notch plays
an essential role in the formation of the inner leaﬂet of the
duplicating ductal plate and also in biliary tubule formation [6–
8,10–16]. These data are consistentwith the association of Alagille
syndrome (AGS) (an autosomal dominant disorder characterized
by ductopenia and cholestasis) with Jag-1 [17,18] (in some cases
Notch-2 [19]) mutations. Beyond development, other important
roles of Notch are emerging that signiﬁcantly impact on liver
physiology and diseases. As will be discussed below, several
studies indicate that the Notch pathway plays a key role in main-
taining liver tissue homeostasis in the post-natal life and is
involved in the reparative reaction to biliary damage, as well as
in liver carcinogenesis, metabolism and inﬂammatory responses.
This review will focus on the involvement of Notch in liver repair
and carcinogenesis and the possible therapeutic implications.14 vol. 60 j 885–890
Clinical Application of Basic Science
Better understanding of the Notch pathway and of its rele-
vance in pathophysiological processes prompted the develop-
ment of a broad spectrum of molecules able to interfere with
its signaling by (1) blocking the activation of Notch receptors
(c-secretase inhibitors or GSIs), (2) blocking the binding of the
ligand (monoclonal antibodies [mAbs], decoys) or (3) blocking
the transcriptional activity of NICD (blocking peptides). Some of
these molecules are in a preclinical phase or in an advanced
phase I clinical trial for cancer treatment (reviewed in [20,21])
(see Fig. 1 and Table 1).
Notch signaling and liver repair
In chronic liver diseases, liver repair requires the concerted
action of epithelial, mesenchymal and inﬂammatory cells. Central
to the cross talk between these cell types are hepatic progenitor
cells (HPCs or reactive cholangiocytes). This cell population,
nearly absent in normal livers, expands signiﬁcantly following
liver injury and expresses an array of inﬂammatory mediators,
cytokines and receptors that help establish the cellular crosstalkDNA
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886 Journal of Hepatology 201needed for epithelial healing. Unfortunately, continuous expan-
sion of this reactive cell population is associated with persistent
inﬂammation, mesenchymal cell activation, and portal ﬁbrosis
[22–24], leading to the deposition of the ﬁbro-vascular stroma
that is ultimately responsible for the architectural distortion of
progressive liver diseases.
Several liver morphogenetic pathways are reactivated in HPCs
during liver repair; for example, Notch acts in concert with Wnt
[25] or Hedgehog [26], to restore liver architecture and function.
In AGS, paucity of bile ducts is associated with impaired biliary
differentiation of HPCs, consistent with the hypothesis that Notch
is a default inducer of biliary speciﬁcation. With comparison to
other cholestatic diseases, in AGS, HPCs are decreased, while
intermediate cytokeratin 7 (K7)-positive hepatocytes accumu-
late, suggesting that HPCs are forced towards the hepatocellular
fate, or that transdifferentiation of hepatocytes into HPCs is
blocked [22]. Of note, HNF1b, a transcription factor critical for bil-
iary speciﬁcation, is down-regulated in the accumulating K7-
positive intermediate hepatocytes. Conversely, a reciprocal
relationship between Hes1 and the transcription factor PDX-1
has been described [27].Fig. 1. Schematic representation of Notch signaling and potential inhibitory
strategies. Notch pathway requires different steps to transmit the signal from the
‘‘transmitting cell’’ to the adjacent ‘‘receiving cell’’. (1) Ligand/receptor binding is
the very ﬁrst step that leads to signaling activation. Notch inhibition can be
achieved by interfering with this step. Recent Notch neutralizing antibodies
proved to be highly speciﬁc for the target isoforms of receptors/ligands. They
target the Notch regulatory region (NRR) on the extracellular portion of the
receptors and can selectively recognize Notch1 (NRR1 mAb [56,57]), Notch2
(NRR2 mAb [57]) or Notch3 (NRR3 mAb [58]) receptors. Other mAbs compete
with endogenous ligand at the ligand-binding domain level [56]. Immunostrat-
egies directed against ligands (i.e., mAbs recognizing Jag1, Dll4, Dll1) showed
inhibited tumor growth and angiogenesis [59]. These antibodies are now in phase
I trials investigation (OMP-59R5 [anti-Notch2-3] and OMP-21M18 [anti-Dll4]).
The high speciﬁcity of mAbs decreases the toxicity that can derive from pan-
Notch inhibition. mAbs can target the desired Notch molecule that is aberrantly
upregulated, sparing the other isoforms. Soluble proteins mimicking Notch
receptors or ligands but lacking the transmembrane portion necessary for signal
activation can be used as Decoys to compete with endogenous Notch1 [60] Jag1
[61] and Dll1 [62]. (2) The next fundamental step relies upon c-secretase
dependent receptor-proteolysis. GSIs are the most investigated Notch-inhibiting
compounds, since they have already been tested in clinical trials to treat
Alzheimer’s disease [63]. GSIs are potent non-selective Notch inhibitors that
target the activating proteolysis of Notch intracellular domain operated by the
c-secretase enzyme and thus inhibit non-speciﬁcally all four Notch receptors
isoforms. GSIs are being tested in phase I clinical trials for T-all leukaemia, breast
cancer and other solid tumors, either alone or in combination with standard of
care treatment. Although appealing, GSIs based therapy suffers from some
drawbacks. GSI might have off target effects on other c-secretase dependent
pathways, and long term GSI treatment leads to intestinal toxicity as a result of
combined Notch-1 and -2 inhibition. Therefore, alternative strategies have been
designed, such as immunotherapy for the extracellular domain of nicastrin (i.e.,
one of the subunit of the c-secretase complex). This antibody recognizes nicastrin
in the active enzymatic complex, thus acting as pan-Notch inhibitor [64]. (3)
Receptor cleavage allows the release of the NICD, which translocates to the
nucleus where it binds the DNA-binding partner RBP-jk and recruits the
co-activator MAML1, necessary for Notch target gene transcription. Also, cell
permeable blocking peptides (dominant negative [DN]-MAML1, stapled peptide
SAHM1) can be used to interfere with the formation of the nuclear complex NICD/
CSL and inhibit the transcriptional activity of NICD. These newly designed
molecules reviewed in [20] are promising but need further investigation. (mAbs,
monoclonal antibodies; GSIs, c-secretase inhibitors; NICD, notch intracellular
domain).
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Table 1. Available Notch-interfering agents and suggested applications for liver diseases treatment.
Blocking strategies Status* Advantages Disavantages Potential liver 
applications
GSIs
γ-secretase inhibitors Preclinical studies
Phase I trials
• Potent non-selective 
pan-Notch inhibitors
• Off-target effects
• Intestinal toxicity
• Dose-limiting complications
Reduce pathologic liver 
repair and fibrogenic
process
Blockage of Notch 
signaling in  liver 
cancer 
Blocking peptides
In vitro studiesDN–MAML1
SAHM1 Preclinical studies
• Small size
• Structural compatibility 
with target protein
• Unknown pharmacokinetics
• Unknown biodistribution
mAbs
In vitro studiesAnti-NRR1, NRR2, NRR3
Anti-N1, N2, N3
Anti-Jag1, Dll1, Dll4
Anti-nicastrin
Preclinical studies
Phase I trials
• Decreased toxicity
High specificity
specific isoform
• 
• Possibility to target a 
• Limited biodistribution
• Unknown pharmacokinetics
Target Jag-1 positive 
mesenchymal cells
Target Notch-1, -2 to 
reduce HPC-driven 
ductular reaction
Selectively target 
Notch-1 or -2 in liver 
cancer cells
Decoys
In vitro studiesSoluble N1, Jag1, Dll1
Preclinical studies
• Small, soluble molecules • Unknown pharmacokinetics
• Unknown biodistribution
Table 1 shows different classes of compounds to inhibit Notch signalling, some of which are under preclinical investigation. These agents block Notch signalling at different
points of the pathway cascade, and each have advantages/disadvantages. Potential applications in liver disease are suggested, albeit fully speculative.
⁄To our knowledge no phase I clinical study is being done in liver diseases. For a full discussion see Refs. [20,21].
JOURNAL OF HEPATOLOGYIn the adult liver, Notch components are expressed in both the
epithelial and mesenchymal compartments, and are differentially
regulated in case of injury. Notch-1 and -2 are expressed in epi-
thelial liver cells and during biliary damage they are upregulated
in cholangiocytes and HPCs [25,28,29], whereas Notch-3 and -4
are expressed in mesenchymal and endothelial cells [30]. Notch-
1 and Notch-3, both expressed by quiescent hepatic stellate cells
(HSC) [26,31,32], are respectively downregulated and upregulated
during HSC transdifferentiation into myoﬁbroblasts. The ligand
Jag-1, has been detected on proliferating bile ductules [25,29,33]
on hepatocytes [31], as well as on activated HSC [26,31,32] and
is strongly upregulated in injured livers. It is worth noting that
in patients with AGS there is limited deposition of ﬁbrotic tissue,
consistent with the slow progression to cirrhosis seen in AGS
patients [34]. Thus, Jag-1, the protein defective in AGS, may signal
to portal myoﬁbroblasts and induce collagen production or prolif-
eration. Indeed, Notch has been recently associated with HSC
transdifferentiation to myoﬁbroblasts. Jag-1 and Notch-2 seem
to play a role in facilitating hedgehog signaling in ﬁbrosis [26].
Notch activation and upregulation of Notch-3 in myoﬁbroblasts
has been described in an experimental rat model of carbon tetra-
chloride (CCl4)-induced liver ﬁbrosis. In this model, pharmacolog-
ical Notch inhibition reduced the extent of liver ﬁbrosis [31].
Mice with liver conditional defect in Notch receptors or in the
common transcription factor RBP-Jj are unable to mount an
effective HPCs response after liver damage [28]. In addition,
Notch-2 is essential for biliary tubular morphogenesis, as in
liver-speciﬁc Notch-2 KO mice the generation of biliary-commit-
ted HPCs is still possible, but tubule formation is impaired [28].
Tubule formation is a fundamental aspect of biliary repair, to
restore the branching architecture of the ductal system. If a
proper branching structure is not regenerated, the ﬁnal result will
be parenchymal necrosis or vanishing bile duct syndrome and
ﬁbrosis, i.e., the ﬁnal stage of several cholangiopathies.Journal of Hepatology 201During liver repair, cell-cell interactions between Notch-
expressing HPCs and Jag-1-expressing portal ﬁbroblasts regulate
biliary speciﬁcation of HPCs. The decision between the hepatocel-
lular and the biliary commitment depends upon the type of
inﬂammatory reaction and the balanced activation of Wnt or
Notch signaling, respectively [25,28,35,36]. The histogenesis of
HPCs is however not completely understood. A recent paper by
Yanger et al. [37], adds further credit to the hypothesis that,
depending on the type of liver injury, reactive cholangiocytes
may actually be generated by a Notch-dependent reprogramming
of hepatocytes. This is consistent with reports showing that intra-
hepatic cholangiocarcinoma (CCA) may also derive from hepato-
cytes [38,39] (see below).
Notch signaling and liver cancer
Liver cirrhosis is a common feature of hepatocellular carcinoma
(HCC) (85–90%) and in an increasing proportion of intrahepatic
CCA (85–90%) [40,41]. The key features of cirrhosis, necroinﬂam-
mation, ﬁbrosis and HPCs-driven hepatic reparative process are
permissive to the reprogramming of HPCs into cancer initiating
cells (cancer stem cells, CSC) [42]. Consistent with this concept,
a subset of tumours that exhibit characteristics of both CCA and
HCC, are thought to arise from the HPCs compartment [43]; some
show gene expression signatures of Notch activation.
On the contrary to T cell acute lymphoblastic leukaemia (T-
ALL) [44] gain-of-function mutations of Notch receptors have
not been reported yet in solid tumours, but there is increasing
evidence that inappropriate Notch pathway activation occurs in
several cancers [20,45], including liver cancers. Pro-mitogenic
functions of Notch in hepatocytes have been shown in experi-
mental models of partial hepatectomy [46,47]; the pro-oncogenic
role of Notch is further supported by genome wide analysis on
HCC samples reporting that among others, the Notch coactivator4 vol. 60 j 885–890 887
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Fig. 2. Pathological conditions possibly involving Notch loss/gain of function,
working hypothesis. Proper Notch activation is fundamental for HPCs biology.
(A) Defective Notch signaling causes AGS, a condition characterized predomi-
nantly by ductopenia and consequent cholestasis. In this context, HPCs are unable
to commit toward the biliary lineage and to re-organize into bile ducts. (B)
Similarly, experimental models of cholestatic liver disease [28] have demon-
strated that Notch inhibition results in altered liver repair process and failure to
regenerate bile ductules. On the contrary, (C) continuous Notch stimulation after
damage may cause pathologic repair resulting in excessive ﬁbrotic tissue
deposition and architectural liver distortion. Moreover, aberrant and persistent
Notch stimulation in HPCs may induce their malignant transformation leading to
(D) HCC and/or (E) CCA. Micrographs represent H&E staining of human samples of
(A) AGS, (C) biliary atresia, (D) HCC, (E) CCA; (B) represents K19 staining of
ductular reactive/HPCs cells during liver repair in a Notch-defective mouse. AGS,
Alagille syndrome; HPC, hepatic progenitor cells; HCC, hepatocellular carcinoma;
CCA, cholangiocarcinoma; K19, cytokeratin-19.
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MAML2 is a target of genetic alterations [48]. Recent studies sug-
gest that Notch signaling is involved in liver oncogenesis by acti-
vating a subset of Sox9 and K19-positive progenitors, (see ref
[9,49] for a discussion of the role of Notch in liver cancer). Mice
with liver-speciﬁc constitutive activation of Notch-1 intracellular
domain (N1ICD [50]) develop HCC once they reach adult age. The
histology of liver lesions in these mice showed features similar to
human HCC and the presence of proliferating K19-positive cells
(most likely CSC). Genomic proﬁling revealed that the Notch-spe-
ciﬁc gene expression signature reported in mice overexpressing
N1ICD was present in a cluster of patients with HCC and was
associated with genes related to cellular proliferation and Sox9
expression [50]. Accordingly, spontaneous development of dedif-
ferentiated HCC occurred in experimental models with constitu-
tive Notch-2 intracellular domain (N2ICD) activation in HPCs
[51]; again, Notch-induced malignant hepatocyte transformation
was associated with the expression of Sox9 and down-regulation
of the hepatocyte-related genes. Interestingly, when overexpres-
sion of N2ICD was associated with the administration of onco-
genic stimuli, foci of CCA developed in the liver. Thioacetamide
treatment in mice overexpressing hepatic N1ICD resulted in a
rapid onset of CCA; fate-tracing studies proved that CCA cells
derived from hepatocytes conversion to a biliary, K19 positive
phenotype [39] as a consequence of ectopic Notch activation.
Accordingly, N1ICD cooperation with AKT signaling in hepato-
cytes stimulated their malignant dedifferentiation leading to
CCA development [38]. These ﬁndings are consistent with
increasing incidence of intrahepatic CCAs in patients with cirrho-
sis of parenchymal origin [52]. Moreover, inﬂammatory media-
tors (i.e., inducible nitric oxide synthase)-stimulated N1ICD
expression was reported in human CCA samples [53], further sup-
porting a malignant role of ectopically expressed Notch in the
liver.
Taken together, these data indicate that persistent activation
of Notch signaling may play an oncogenic role depending on
modiﬁer factors, such as the inﬂammatory ﬁeld or the presence
of other carcinogenetic conditions, potentially giving rise to
either HCC with stem cell features or to CCA.
Potential Notch-based therapeutic strategies
The ﬁndings discussed above provide an intriguing rationale for
Notch-based therapies in patients with liver diseases. Ductular
reactive cells and HPCs express Notch-1 and -2 receptors, which
can be activated by neighbouring cells (including Jag-1 positive
mesenchymal cells) thereby regulating liver repair and regenera-
tive processes [25,26,28]. GSIs efﬁciently inhibited Notch signal-
ing in mouse models of cholestatic liver disease [28] and reduced
ﬁbrosis in CCl4-treated rodents [31]. It is interesting to speculate
that GSIs may be used to inhibit ductular reaction and HSC acti-
vation, thereby reducing the extent of liver ﬁbrosis and architec-
tural distortion. Unfortunately, acting on all signaling pathways
requiring proteolytic cleavage of the receptor, GSIs are not cell
selective, neither system-speciﬁc. In addition, GSIs have a consid-
erable toxicity proﬁle, mainly affecting gut functionality, as a
result of combined Notch-1 and -2 inhibition disrupting intesti-
nal stem cell biology [54]. Thus, the use of the more selective
monoclonal antibodies against Notch-1 and -2 or Jag-1 may pro-
vide a considerable advantage.
As discussed above, both HCC and CCA may arise when Notch
is aberrantly and/or ectopically activated in experimental models888 Journal of Hepatology 201[38,39,50,51,55]. Identiﬁcation of a Notch signature, a fundamen-
tal step to design a targeted treatment, was reported in a subset
of HCC patients [50], and Notch receptors were found overexpres-
sed in human CCAs [55]. These subsets of liver cancers may be
good candidates for Notch-inhibition strategies. Silencing the
Notch pathway could potentially abrogate Notch-driven tumor
progression and also interfere with tumor aggressiveness, given
that Notch activation has been associated to a more malignant4 vol. 60 j 885–890
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phenotype [39,50,51]. The presence of a reliable tissue-speciﬁc
biomarker of Notch inhibition would be critical to apply Notch-
directed therapy. Interestingly, the hepatic Notch target gene
Sox9 [8], has been associated with a worse prognosis in liver can-
cers [50]. Therefore, the role of Sox9 as a potential biomarker of
Notch involvement and indication for Notch-targeted treatment
should be explored.Conclusions
Notch is being increasingly recognized as a major signaling
mechanism in liver biology and in multiple pathophysiological
conditions, from liver repair to carcinogenesis (Fig. 2). Indeed,
Notch is necessary to regulate HPCs speciﬁcation toward the bil-
iary lineage and to orchestrate the reparative remodelling of the
biliary tree [28]. However, the functional role of Notch in regulat-
ing HPCs/mesenchymal cross-talk during ﬁbrogenic pathologic
repair remains to be fully unveiled. Similarly, the oncogenetic
action of Notch in liver malignancies requires further investiga-
tion, since persistent activation of this signaling has been associ-
ated to both, HCC and CCA.
Notch emerges as a potential therapeutic target, however, the
chances of success of Notch-targeted strategies depend on a
variety of factors. First of all, Notch activation has different
effects depending on cellular and tissue context, in both physio-
logic and pathologic states. Second, Notch is strictly connected
with other signaling mechanisms, indicating that combination
therapies targeting also other signaling (for example Hedgehog)
may be more effective to target pathologic liver repair and car-
cinogenesis. Thus, more efforts are needed to understand the
molecular mechanisms regulating Notch activation in a speciﬁc
cell context and the complex interplay with additional partners
involved.
Key Points
• In the liver, Notch signaling is critical for biliary tree 
formation by committing hepatoblasts toward the 
cholangiocyte-fate and by orchestrating tubulogenesis. 
Defective Notch signaling causes Alagille Syndrome 
with ductopenia and cholestasis
• Notch activation has been demonstrated in response 
to liver damage, where it appears to be fundamental 
for regenerating damaged cholangiocytes and bile 
ductules
• Persistent activation of Notch eventually leads to 
pathologic liver repair and fibrosis; preliminary studies 
suggest Notch inhibition may reduce liver fibrosis in 
experimental models
• Ectopic and persistent Notch activation in the liver 
may be linked to hepatic cancer. Interestingly both 
HCC and CCA have been described in animal models 
overexpressing Notch in liver epithelial cells
• Understanding the pathophysiological role of Notch 
in liver disease may turn out to be of therapeutic 
relevance, in fact several therapeutic tools are being 
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